Company Analysis
Sign in

Adlai Nortye Ltd. (ANL)

Nasdaq: ANL · Pharmaceutical Preparations · North Brunswick, NJ · filing with the SEC since 2022
Full chart Alerts Compare
Grade4.6
◀ Past 5.1● Present 3.0▶ Future 5.6
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2023, as filed
Revenue$5.0M-89.1%
Net income-$109M-85.8%
Earnings per share$-2.52-9.1%
Operating cash flow-$56.7M-31.1%
Cash$91.5M+114.0%
Debt$30.4M+604.8%
Shareholders’ equity$75.0M+131.1%
Shares, diluted43.3M+70.4%
Return on equity-203.5%
The recordfrom its filings
Filings in 202650
Newest filingOct 28 · 6-K
Annual reportApr 10, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$400,000
Insider buys, 12 months$0.00
Patents granted5
Filer categoryNon-accelerated filer<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
21222324
As filed, in USD. Nothing here is a forecast.

News

Oct 1, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 24, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 15, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ANL · research, not advice